![Giedrius Zunda](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Giedrius Zunda
Hoofd Techniek/Wetenschap/O&O bij
ALVOTECH
Profiel
Giedrius Zunda is currently working as the Chief Technology Officer at Alvotech.
Previously, he worked as the Chief Executive Officer at Northway Biotech, Inc. He has a graduate degree from Vilniaus Gedimino Technikos Universitetas and an MBA from Baltic Management Institute.
Actieve functies van Giedrius Zunda
| Bedrijven | Functie | Begin |
|---|---|---|
| ALVOTECH | Hoofd Techniek/Wetenschap/O&O | 01-01-2023 |
Eerdere bekende functies van Giedrius Zunda
| Bedrijven | Functie | Einde |
|---|---|---|
Northway Biotech, Inc.
 Northway Biotech, Inc. Marine ShippingTransportation Northway Biotech, Inc. is a contract development and manufacturing organization (CDMO) specializing in protein-based biologics, gene therapies, plasmid DNA, and viral vectors. The private company is based in Waltham, MA. The company provides end-to-end services including cell line development (mammalian and microbial), process development, analytical methods, formulation development, viral clearance studies, cGMP manufacturing (cell banking, drug substance, and drug product), and aseptic fill-finish. Its manufacturing capabilities feature scalable mammalian cell culture and microbial fermentation using bioreactors up to 4000 L and 3000 L, respectively, with strict separation of microbial and mammalian processes. Northway Biotech ensures regulatory compliance with FDA and EMA standards, offering quality assurance, quality control, and regulatory affairs support for product safety and successful submissions. The company participates in EU-funded research projects focused on biosimilar monoclonal antibodies and innovative microbial biosynthesis technologies, integrating molecular biology, genetic engineering, and biotechnology to deliver scalable bioprocesses. The CEO of the company is Vladas Algirdas Bumelis. | Algemeen Directeur | - |
Opleiding van Giedrius Zunda
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
4
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Baltic Management Institute
 Baltic Management Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vilniaus Gedimino Technikos Universitetas
 Vilniaus Gedimino Technikos Universitetas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alvotech
 Alvotech BiotechnologyHealth Technology Develops biologic medicines | Health Technology |
Northway Biotech, Inc.
Northway Biotech, Inc. Marine ShippingTransportation Northway Biotech, Inc. is a contract development and manufacturing organization (CDMO) specializing in protein-based biologics, gene therapies, plasmid DNA, and viral vectors. The private company is based in Waltham, MA. The company provides end-to-end services including cell line development (mammalian and microbial), process development, analytical methods, formulation development, viral clearance studies, cGMP manufacturing (cell banking, drug substance, and drug product), and aseptic fill-finish. Its manufacturing capabilities feature scalable mammalian cell culture and microbial fermentation using bioreactors up to 4000 L and 3000 L, respectively, with strict separation of microbial and mammalian processes. Northway Biotech ensures regulatory compliance with FDA and EMA standards, offering quality assurance, quality control, and regulatory affairs support for product safety and successful submissions. The company participates in EU-funded research projects focused on biosimilar monoclonal antibodies and innovative microbial biosynthesis technologies, integrating molecular biology, genetic engineering, and biotechnology to deliver scalable bioprocesses. The CEO of the company is Vladas Algirdas Bumelis. | Transportation |
Kies MarketScreener 
